Drug intelligence / Profile preview

recombinant anti-human IL6 nanobody

Development stage: Preclinical
Lead developer: Creative BioMart
Modality: Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

Recombinant anti-human IL6 nanobody is a therapeutic nanobody developed through a collaboration between Creative BioMart and an undisclosed U.S. pharmaceutical giant. This nanobody specifically targets human Interleukin-6 (IL6), a key cytokine involved in immunology and inflammation. The agreement, signed in September 2013, includes the supply of bulk quantities of the nanobody by Creative BioMart and collaborative efforts for its development and commercialization as a novel immunomodulatory therapeutic for inflammatory conditions and immunology indications.

Targets

IL-6 (Interleukin 6)

Beyond the preview

Go deeper on recombinant anti-human IL6 nanobody.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant anti-human IL6 nanobody.

Explore the full profile